WO1999042002A1 - Mineralized drinking water and method of making same - Google Patents

Mineralized drinking water and method of making same Download PDF

Info

Publication number
WO1999042002A1
WO1999042002A1 PCT/US1998/003347 US9803347W WO9942002A1 WO 1999042002 A1 WO1999042002 A1 WO 1999042002A1 US 9803347 W US9803347 W US 9803347W WO 9942002 A1 WO9942002 A1 WO 9942002A1
Authority
WO
WIPO (PCT)
Prior art keywords
water
ions
liter
calcium
magnesium
Prior art date
Application number
PCT/US1998/003347
Other languages
French (fr)
Inventor
John A. Lindon
Arthur Malin
Original Assignee
Lindon Hearty Water, Llc
Malin Hearty Water, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lindon Hearty Water, Llc, Malin Hearty Water, Llc filed Critical Lindon Hearty Water, Llc
Priority to PCT/US1998/003347 priority Critical patent/WO1999042002A1/en
Priority to AU66615/98A priority patent/AU6661598A/en
Publication of WO1999042002A1 publication Critical patent/WO1999042002A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/42Preservation of non-alcoholic beverages
    • A23L2/50Preservation of non-alcoholic beverages by irradiation or electric treatment without heating
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16Inorganic salts, minerals or trace elements

Definitions

  • the high incidence of hypertension is significantly related to the intake of sodium, and reducing sodium in the diet reduces hypertension. It is therefore advantageous to rid the body of excess sodium.
  • Each of the ionic forms of the elements appear to cont ⁇ bute to the prevention of cardiovascular disease in va ⁇ ous ways.
  • the introduction of lithium salts into the mineralized formulation acts as a natural diuretic removing excess or harmful levels of sodium, potassium and water, thereby reducing the incidence of hypertension and other cardiovascular conditions that may be induced by the presence of excessive sodium salts.
  • Lithium also appears to have blood glucose lowering effects in hyperglycemic subjects.
  • Acting in concert with the lithium salts are the water-soluble magnesium salts, which are very important as an activator of many enzymes, such as those concerned with the metabolism of adenosme triphosphate (ATP) and those essential for maintaining healthy myocardial tissues and healthy myocardial functioning.
  • ATP adenosme triphosphate
  • Magnesium salts are found to aid in preventing "sudden death" after myocardial infraction possibly by reducing the incidence and degree of cardiac arrhythmias following infraction, and by protecting against cardiotoxic agents.
  • Calcium and strontium salts too, have been found to reduce cardiovascular disease, possibly by competing with sodium and potassium for intestinal absorption and by increasing excretion of sodium.
  • the mineralized water of the invention has no sodium ion (l e table salt)
  • the high incidence of hypertension is significantly related to the intake of sodium, from both food and water 5
  • the mineralized water of the invention causes less sodium to be absorbed from the gut because its minerals complete with sodium m the intestinal lumen (gut) for absorption Thus, much of the sodium ingested with food is not absorbed from the gut, but is instead excreted with bowel waste mate ⁇ al
  • the o mineralized water b ⁇ ngs about increased u ⁇ nary excretion of sodium by diuretic action and by the minerals competing with the kidneys for re-absorption Accordingly, the kidneys get ⁇ d of more sodium
  • the positive health effects of magnesium and calcium also include (1) 5 lowe ⁇ ng the blood cholesterol levels, particularlv of the low-density hpoprotein
  • LDL low-density lipoprotein
  • Chromium deficiency in the human body can lead to numerous health problems including impaired glucose tolerance fasting hyperglycemia [abnormally high blood sugar] elevated circulating insulin elevated blood cholesterol - elevated blood triglycerides decreased HDL cholesterol peripheral neuropathy [damage to peripheral nerves in the body] brain disorders
  • the recommended safe and adequate adult daily intake for chromium is 50 to 200 micrograms. However, those are reliable indications that females and males are consuming roughly 40 and 60 percent of the suggested minimum, respectively.
  • the potable water of the invention provides an ideal vehicle to carry the essential mineral chromium, magnesium, calcium and lithium, in an ionic form which is easy to consume, and which is easily absorbed into the bloodstream.
  • the mineralized water of this invention consists essentially of the following ingredients, ranges and proportions, viz an aqueous solution of:
  • the stated metallic ions are added to distilled water in the form of water soluble salts thereof, e g., as the sulphates, nitrates, or chlo ⁇ des. No sodium is added.
  • One presently preferred method of preparation of the mineralized water of this invention utilizes a distilled water base into which the predetermined concentration of e.g., chromium chlo ⁇ de, magnesium sulphate, calcium chlo ⁇ de, and lithium chlo ⁇ de are added.
  • the predetermined concentration of e.g., chromium chlo ⁇ de, magnesium sulphate, calcium chlo ⁇ de, and lithium chlo ⁇ de are added.
  • Other forms of salts can also be utilized.
  • the resulting mineralized water is then packed in suitable containers for later dist ⁇ bution and use

Abstract

An optimal mineralized potable or drinking water formulation. The optimal mineralized drinking water formulation has great utility in preventing cardiovascular disease and improved blood glucose levels, and related blood conditions, and is an aqueous solution consisting essentially of: 10-100 mcg/liter Chromium ions; 50-100 mg/liter Magnesium ions; 60-125 mg/liter Calcium ions; and 0.06-0.15 mg/liter Lithium. All the chemical elements are present in the ionic form as water soluble salts, e.g., as sulfates, nitrates, or chlorides of the elements. The mineral water contains no sodium ions. The minerals can also be in a kit form for adding to water by an end user.

Description

MINERALIZED DRINKING WATER AND METHOD OF MAKING SAME
BACKGROUND OF THE INVENTION
There is significance epidemiological evidence found in the literature indicating that the drinking of certain kinds of naturally occurring mineralized waters have the effect of decreasing mortality due to cardiovascular disease. Examples of the most relevant literature of which we are presently aware attesting 5 to such epidemiological evidence are the following publications:
1 ) "MAGNESIUM AND THE HEART," American Heart Journal, June, 1977, Vol. 93, No. 6, pp. 679, 682, B & J. R. Chipperfield; 0
2) "RELATIONSHIP OF METAL METABOLISM TO VASCULAR DISEASE MORTALITY RATES IN TEXAS," The American Journal of Clinical Nutrition, 31 ; July 1978, pp. 1 188-1 197, E.B. 5 Dawson et al;
3) "WATER HARDNESS AND CARDIOVASCULAR MORTALITY," Annals New York Academy of Sciences, 0077-8923/78/0304-0203, pp. 203 - 219, o Neir and Johansen; 1978;
4) "MINERALS, CORONARY HEART DISEASE AND SUDDEN CORONARY DEATH," Adv. Cardioll, Vol. 25, pp. 9 - 24, H. Karppanen et al.; 5 1978; 5) "DRINKING WATER QUALITY AND SUDDEN
DEATH," Adv. Cardiol. Vol. 25, pp. 25 - 26, 1978 S. Punsar et al.
5 6) "MAGNESIUM IN ATHEROSCLEROTIC
CARDIOVASCULAR DISEASE AND SUDDEN DEATH." Acta Cardiologica, Vol. 36, 1981.
7) "GEOCHEMISTRY, SOILS AND i o CARDIOVASCULAR DISEASE" by R. Masironi,
Division of Non-Communicable Diseases, World Health Organization, Geneva, Switzerland, Experienta, 1987.
is 8) "MAGNESIUM AND CERTAIN OTHER ELEMENTS AND
CARDIOVASCULAR DISEASE" in The Science of Total Environment. Elsevier Science Publishers, Amsterdam, 1985.
9) "WATER HARDNESS AND CARDIOVASCULAR o MORTALITY," Annals of the New York Academy of Sciences, 1978.
10) "MORTALITY AND THE CONCENTRATION OF ELEMENTS IN TAP WATER IN COUNTY
25 BOROUGHS IN ENGLAND AND WALES,"
British Journal of Preventive and Social Medicine,
1977.
1 1 ) "ISCHEMIC HEART DISEASE. WATER
3 o HARNESS AND MYOCARDIAL MAGNESIUM,"
CMA Journal, August, 1975; 12) "A REVIEW OF SOME EPIDEMIOLOGICAL FACTORS IN CORONARY HEART DISEASE," The Journal of Medical Society of New Jersey, December, 1975.
5
13) "SHOULD MAGNESIUM THERAPY BE CONSIDERED FOR THE TREATMENT OF CORONARY HEART DISEASE? II. EPIDEMIOLOGICAL EVIDENCE IN o OUTPATIENTS WITH AND WITHOUT
CORONARY HEART DISEASE" by B. Lasserre, M. Spoerri, V. Moullet, M.P Theubet in Magnesium Research (1994 Jun); 7(2): 145-53. [Switzerland]
s 14) "IS HYPOMAGNESEMIA
ARRHYTHMOGENIC?" by T.A. Millane, D.E. Ward, A.J. Camm in Clinical Cardiology (1992 Feb); 15(2):103-8. [London, England.]
0 15) "MINERALS, CORONARY HEART DISEASE AND SUDDEN
CORONARY DEATH," Advances in Cardiology, Volume 25, Basel, 1978.
16) "RELATIONSHIP OF METAL METABOLISM TO VASCULAR 5 DISEASE MORTALITY RATES IN TEXAS," by E.B. Dawson in
American Journal of Clinical Nutrition, 1978.
17) "NEW CONCEPTS IN THE CARDIOPROTECTIVE ACTION OF MAGNESIUM AND TAURINE DURING THE CALCIUM o PARADOX AND ISCHAEMIA OF THE HEART" by M.S. Suleiman in Magnesium Research ( 1994 Dec); 7(3-4):295-312. [Bristol, England].
18) "MAGNESIUM ANTAGONIZES THE ACTIONS OF
5 LYSOPHOSPHATIDYL CHOLINE (LPC) IN MYOCARDIAL
CELLS: A POSSIBLE MECHANISM FOR ITS ANTIARRHYTHMIC EFFECTS" by R.C. Prielipp, J.F. Butterworth IV, P.R. Roberts, K.W. Black, G.P. Zaloga in Anesthesiology Analog (1995 Jun); 80(6): 1083-7. 0
19) "PREVENTIVE EFFECTS OF MAGNESIUM ON RAISED SERUM LIPID PEROXIDE LEVELS AND AORTIC CHOLESTEROL DEPOSITION IN MICE FED AN ATHEROGENIC DIET" by Y. 5 Yamaguchi, S. Kitagawa, M. Kunitomo, M. Fijiwara in Magnesium Research (1994 Mar); 7(l ):31-7. [Japan]
20) "COMBINED EFFECTS OF MAGNESIUM o DEFICIENCY AND AN ATHEROGENIC LEVEL
OF LOW DENSITY LIPOPROTEIN ON UPTAKE AND METABOLISM OF LOW DENSITY LIPOPROTEIN BY CULTURED HUMAN ENDOTHELIAL CELLS. II. ELECTRON 5 MICROSCOPIC DATA" by S. Yokoyama, J. Gu, S.
Kashima. H.I. Nishida. T.L. Smith, F.A. Kummerow in Magnesium Research (1994 Jun); 7(2):97-105.
21 ) "EFFECT OF WATER CONTAINING CALCIUM o AND MAGNESIUM SULFATES ON THE
ELIMINATION OF CHOLESTEROL IN THE RAT" by C. Troussaint, E. Peuchant, C. Courtes, R. Jensen, J. Canellas in Archive of Int. Physiological Biochemistry ( 1988 Jun); 96(2): 89- 100. [Bordeaux, France]
5
22) "SERUM AND ERYTHROCYTE MAGNESIUM CONCENTRATIONS AND MIGRAINE" by J. Thomas, E. Thomas, E. Tomb m Magnesium Research (1992 Jun); 5(2):127-30. 0
23) "PREVENTION OF THE RECURRENCE OF URINARY LITHIASIS: MINERAL WATER WITH HIGH OR LOW CALCIUM CONTENT?" by M. Sommaπva, P. Rigatti, M.R. Viola in Minerva Med s (1987 Dec 31); 78(24): 1823-9. [Published in Italian.
Milan, Italy]
24) "ABSORBABILITY OF THE CALCIUM IN A HIGH-CALCIUM MINERAL WATER" by R.P. 0 Heaney, M.S. Dowell in Osteoporosis International
(1994 Nov); 4(6):323-4.
25) MAGNESIUM AND GLUCOSE METABOLISM" by P.J. Lefebvre. G. Paolisso, A.J. Scheen in 5 Therapie (1994 Jan-Feb); 49(1): 1-7. [Pubhshed in
French. Belgium.]
26) "CHROMIUM NUTRITION IN THE ELDERLY" by R.A. Anderson from Vitamin and Mineral o Nutπtion Laboratory, Beltsville Human Nutrition
Research Center, U.S. Department of Agπculture, Agricultural Research Service. Beltsville, MD in Handbook of Nutπtion in the Aged. R.R. Watson, Ed; CRC Press, Boca Raton, FL, pp. 385-92, 1994.
27) "SERUM CHROMIUM AND
ANGIOGRAPHICALLY DETERMINED CORONARY ARTERY DISEASE" by H.A. Newman, R.F. Leighton, R.R. Lanese, N.A. Freeland in Clinical Chemistry ( 1978 April) 24(4):541-4.
28) "CHROMRJM DEFICIENCY AND
CARDIOVASCULAR RISK" by M. Simonoff in Cardiovascular Research (1984 Oct); 19(10):591-6.
29) "CHROMIUM DEPLETION IN THE
PATHOGENESIS OF DIABETES AND ATHEROSCLEROSIS" by E. Boyle Jr., B. Modschein, H.H. Dash in Southern Medical Journal (1977 Dec); 70(12): 1449-53.
30) "CHROMIUM AND CHOLESTEROL-INDUCED ATHEROSCLEROSIS IN RABBITS" by A.S. Abraham, B.A. Brook, U. Eylath in Annals of Nutritional Metabolism ( 1991 )35(4):203-7.
31 ) "RECENT ADVANCES IN THE CLINICAL AND BIOCHEMICAL EFFECTS IN CHROMIUM DEFICIENCY" by R.A. Anderson from Vitamin and Mineral Nutrition Laboratory, Belsville Human Nutrition Research Center. U.S. Department of
Agriculture, Agricultural Research Service, Beltsville. MD in Essential and Toxic Trace Elements in Human Health and Disease: An Update, pp.221-34, 1993.
The high incidence of hypertension is significantly related to the intake of sodium, and reducing sodium in the diet reduces hypertension. It is therefore advantageous to rid the body of excess sodium.
In U.S. Patent No. 4,325,975 "Mineralized Drinking Water and Method of Making Same," the inventors herein obtained patent coverage on a drinking water including strontium, magnesium, calcium and lithium salts. No mention or suggestion was made to include chromium salts.
However, neither the naturally occurring drinking waters of which we are aware nor any manufactured waters provide a formulation for mineralized drinking water which, in our opinion, is an optimum formulation in terms of maximizing the decrease in both the incidence of cardiovascular disease and the mortality rate due to cardiovascular disease.
BRIEF SUMMARY OF THE INVENTION
The optimal mineralized drinking, i.e., potable water formulation strongly appears to have great utility in preventing cardiovascular diseases and is an aqueous solution consisting essentially of:
10- 100 mcg/liter Chromium ion; 50-100 mg/liter Magnesium ions; 60-125 mg/liter Calcium ions; and 0.06-0.15 mg/liter Lithium ions. All the chemical elements are present in the ionic form - as water soluble salts, e.g., as sulfates. nitrates, or chlorides of the elements. The mineral water contains no sodium ions.
This precise combination of ingredients, and the concentration thereof, are believed to be most beneficial in preventing various cardiovascular diseases, especially hypertensive heart disease, hypertension, arteπosclerotic and degenerative heart disease, and generalized arteriosclerosis.
Each of the ionic forms of the elements appear to contπbute to the prevention of cardiovascular disease in vaπous ways. The introduction of lithium salts into the mineralized formulation acts as a natural diuretic removing excess or harmful levels of sodium, potassium and water, thereby reducing the incidence of hypertension and other cardiovascular conditions that may be induced by the presence of excessive sodium salts. Lithium also appears to have blood glucose lowering effects in hyperglycemic subjects. Acting in concert with the lithium salts are the water-soluble magnesium salts, which are very important as an activator of many enzymes, such as those concerned with the metabolism of adenosme triphosphate (ATP) and those essential for maintaining healthy myocardial tissues and healthy myocardial functioning. Magnesium salts are found to aid in preventing "sudden death" after myocardial infraction possibly by reducing the incidence and degree of cardiac arrhythmias following infraction, and by protecting against cardiotoxic agents. Calcium and strontium salts, too, have been found to reduce cardiovascular disease, possibly by competing with sodium and potassium for intestinal absorption and by increasing excretion of sodium.
Calcium also has significant hypohpemic effects (reducing fat in the blood).
The literature is voluminous on the advantages of reduced cardiovascular disease fortuitously occurring to those who happen to live in areas of the world which have naturally occurring highly mineralized waters. For example. West
Texas is reputed to have both the hardest, most heavily mineralized drinking water and the lowest cardiovascular mortality rates m the United States, a country which has the second highest national cardiovascular mortality rate m the world. See "Relationship of Metal Metabolism to Vascular Disease Mortality Rates m Texas," by E B Dawson in Ameπcan Journal of Clinical Nutπtion. 1978 However, of the 5 pπor art references of which the inventors are aware, none attempt to produce a mineralized potable water which has a zero sodium level, together with a combination of metals (in the form of water-soluble salts thereof) having known positive effects in decreasing the incidence and the effects of cardiovascular disease - and making this mineralized water available to the general public 0 regardless of their geographical location.
As noted above, the mineralized water of the invention has no sodium ion (l e table salt) The high incidence of hypertension is significantly related to the intake of sodium, from both food and water 5
The mineralized water of the invention causes less sodium to be absorbed from the gut because its minerals complete with sodium m the intestinal lumen (gut) for absorption Thus, much of the sodium ingested with food is not absorbed from the gut, but is instead excreted with bowel waste mateπal In addition, the o mineralized water bπngs about increased uπnary excretion of sodium by diuretic action and by the minerals competing with the kidneys for re-absorption Accordingly, the kidneys get πd of more sodium
The positive health effects of magnesium and calcium also include (1) 5 loweπng the blood cholesterol levels, particularlv of the low-density hpoprotein
(LDL), the so-called bad form of cholesterol which clogs arteπes, (2) improvements in the state of migraine patients, (3) reducing the incidence of recurπng kidnev stones, and (4) reducing diabetes
o Chromium deficiency in the human body can lead to numerous health problems including impaired glucose tolerance fasting hyperglycemia [abnormally high blood sugar] elevated circulating insulin elevated blood cholesterol - elevated blood triglycerides decreased HDL cholesterol peripheral neuropathy [damage to peripheral nerves in the body] brain disorders
There is significant evidence that people with coronary artery disease have a lower serum chromium concentration than do those patients with normally patent (open) arteries.
The recommended safe and adequate adult daily intake for chromium is 50 to 200 micrograms. However, those are reliable indications that females and males are consuming roughly 40 and 60 percent of the suggested minimum, respectively.
The potable water of the invention provides an ideal vehicle to carry the essential mineral chromium, magnesium, calcium and lithium, in an ionic form which is easy to consume, and which is easily absorbed into the bloodstream.
DESCRIPTION OF THE PREFERRED EMBODIMENT
The mineralized water of this invention consists essentially of the following ingredients, ranges and proportions, viz an aqueous solution of:
10-100 mcg/liter Chromium ions; 50-100 mg/liter Magnesium ions; 60-125 mg/liter Calcium ions; and 0.06-0.15 mg/liter Lithium ions.
10 The optimal formulation lies at or near the upper limits stated above
The stated metallic ions are added to distilled water in the form of water soluble salts thereof, e g., as the sulphates, nitrates, or chloπdes. No sodium is added.
One presently preferred method of preparation of the mineralized water of this invention utilizes a distilled water base into which the predetermined concentration of e.g., chromium chloπde, magnesium sulphate, calcium chloπde, and lithium chloπde are added. Other forms of salts can also be utilized.
The resulting mineralized water is then packed in suitable containers for later distπbution and use
It is also within the scope of this invention to prepare the potable mineralized water by simply adding a tablet, capsule, pellet or powder containing the water soluble salts of the metals to distilled water m a sufficient amount of produce the aforedescπbed concentration limits of metallic ions in the water, i.e.,
10-100 mcg/liter Chromium ions,
50-100 mg/liter Magnesium ions, 60-125 mg/liter Calcium ions; and 0 06-0.15 mg/liter Lithium ions.
The optimal formulation lies at or near the upper limits stated above
The epidemiological evidence indicates that the optimum formulation of mineralized water for daily ingestion purposes, I e., for use as a dπnking water, should not only contain the metallic ions of the foregoing salts but should be devoid of sodium salts A mineralized water based on this formulation does not appear in nature to the best of our knowledge yet appears to offer to offer
11 maximum protection against the development and effects of cardiovascular disease.
Vaπous modifications of the inventions will be apparent to those skilled in the art. We intend, therefore, to be bound only by the claims which follow.
12

Claims

WE CLAIM
1 A sodium free mineralized dπnking water formulation which consists essentially of an aqueous solution containing, 10-100 mcg/liter Chromium ions;
50-100 mg/liter Magnesium ions, 60-125 mg/hter Calcium ions; and 0 06-0 15 mg/hter Lithium ions, each of said ions being present in association with water-soluble salts
2 The sodium free mineralized dnnkmg water formulation of Claim 1, wherein said ions are in distilled water
3 A solid formulation which consists essentially of 0.01-0 10 parts, by weight, of chromium in a water-soluble salt thereof;
50-100 parts, by weight, of magnesium in a water-soluble salt thereof,
60-125 parts, by weight, of calcium in a water-soluble salt thereof, and
0 06-0 15 parts, by weight, lithium in a water-soluble salt thereof
4 The solid formulation of Claim 3, further compπsing 20-40 parts, by weight, of strontium in a water-soluble salt thereof
5 The solid formulation of Claim 3 in tablet form
The solid formulation of Claim 3 in a powder form
The solid formulation of Claim 3 in a capsule form
13
8. The solid formulation of Claim 3, which when added to a predetermined volume of distilled water, produces an aqueous solution containing:
10-100 mcg/liter Chromium ions; 50-100 mg/liter Magnesium ions; 60-125 mg/liter Calcium ions; and
0.06-0.15 mg/liter Lithium ions.
9. The method of making a potable water which comprises the step of: adding to distilled water, water-soluble salts consisting essentially of chromium, magnesium, calcium and lithium in an amount sufficient to produce a concentration range of between
10-100 mcg/liter Chromium ion; 50-100 mg/liter Magnesium ion; 60-125 mg/liter Calcium ion; and 0.06-0.15 mg/liter Lithium ion in said distilled water.
10. The method of Claim 9, wherein said water-soluble salts are added in tablet form.
1 1. The method of Claim 9, wherein said water soluble salts are added in powder form.
12. The method of Claim 9, wherein said water-soluble salts are added in capsule form.
14 AMENDED CLAIMS
[received by the International Bureau on 21 June 1999 (21.06.99); original claims 1-12 replaced by amended claims 1-22 (5 pages)]
1 A sodium free mineralized dnnkmg water formulation of an aqueous solution compnsmg:
0.010-0.100 mg/hter Chromium ions, 50-100 mg/liter Magnesium ions. 60-125 mg hter Calcium ions: and
0 06-0.15 mg/hter Lithium ions, each of said ions being present in association with water-soluble salts.
2 The sodium free mineralized dπnking water formulation of Claim 1. wherein said ions are in distilled water
3 The sodium free mineralized dnnkmg water formulation of Claim 1 or 2, further compπsing a concentration of Potassium ions less than or equal to the concentration of said Calcium ions.
4 A sodium free solid formulation which comprises: 0.01-0.10 parts, by weight, of chromium in a water-soluble salt thereof;
50-100 parts, by weight, of magnesium in a water-soluble salt thereof;
60-125 parts, by weight, of calcium in a water-soluble salt thereof; and
0.06-0.15 parts, by weight, lithium in a water-soluble salt thereof
5 The solid formulation of Claim 4. further compπsing 20-40 parts, bv weight, of strontium in a water-soluble salt thereof.
6 The solid formulation of Claim 4 or 5. further compπsing a
15 concentration of potassium less than or equal to the concentration of calcium, in a water-soluble salt thereof.
7. The solid formulation of any one of Claims 4, 5 or 6 in tablet form.
8. The solid formulation of any one of Claims 4, 5 or 6 in a powder form.
9. The solid formulation of any one of Claims 4, 5 or 6 in a capsule form.
10. The solid formulation of Claim 4, which when added to a predetermined volume of distilled water, produces an aqueous solution contaimng: 0.010-0.100 mg/hter Chromium ions;
50-100 mg/liter Magnesium ions; 60-125 mg/liter Calcium ions; and 0.06-0.15 mg/liter Lithium ions.
11. The solid formulation of Claim 6, which when added to a predetermined volume of distilled water, produces an aqueous solution containing- 0.010-0.100 mg/hter Chromium ions; 50-100 mg hter Magnesium ions; 60-125 mg liter Calcium ions; and 0.06-0.15 mg/hter Lithium ions; -and a concentration of Potassium ions less than or equal to the concentration of said Calcium ions.
12. The method of making a potable sodium free water which compπses the step of: adding to distilled water, water-soluble salts compπsing chromium,
16 magnesium, calcium and lithium in an amount sufficient to produce a concentration range of between
0.010-0.100 mg/liter Chromium ions;
50-100 mg/liter Magnesium ions; 60-125 mg/liter Calcium ions; and
0.06-0.15 mg/liter Lithium ions in said distilled water.
13. The method of Claim 12, further comprising adding to the distilled water, a water soluble salt of potassium in an amount sufficient to produce a concentration of potassium ions less than or equal to the concentration of Calcium ions.
14. The method of Claim 12 or 13, wherein said water-soluble salts are added in tablet form.
15. The method of any one of Claims 12, 13 or 14, wherein said water soluble salts are added in powder form.
16. The method of any one of Claims 12, 13 or 14, wherein said water-soluble salts are added in capsule form.
17. A sodium free mineralized drinking water formulation of an aqueous solution comprising: 0.010-0.100 mg/liter Chromium ions;
50-100 mg/liter Magnesium ions;
60-125 mg liter Calcium ions;
0.06-0.15 mg/liter Lithium ions; and less than 125 mg/liter Potassium ions, each of said ions being present in association with water-soluble salts.
17
18 The sodium free mineralized dnnkmg water formulation of Claim 17, wherein said ions are in distilled water
19. A sodium free mineralized dnnking water formulation which compπses an aqueous solution containing:
0.01-0.08 mg/hter Chromium ions; 30-100 mg/hter Magnesium ions; 30-125 mg/hter Calcium ions; 0.06-0.15 mg/hter Lithium ions; and 10- 100 mg/hter Potassium ions, each of said ions being present in association with water-soluble salts.
20. The sodium free mineralized drinking water formulation of claim 19, where in said ions are m distilled water.
21. A solid sodium free formulation which comprises: 0.01-0.08 parts, by weight, of chromium in a water-soluble salt thereof; 30-100 parts, by weight, of magnesium m a water-soluble salt thereof;
30-125 parts, by weight, of calcium in a water-soluble salt thereof; 0.06-0.015 parts, by weight, of lithium in a water-soluble salt thereof; and 10- 100 parts, by weight, potassium in a water-soluble salt thereof.
22. The method of making a potable water which compπses the step of: adding to distilled water, water-soluble salts comprising chromium, magnesium, calcium, lithium and potassium in an amount sufficient to produce a concentration range of between:
18
0.01-0.08 mg/liter Chromium ions;
30-100 mg/liter Magnesium ions;
30-125 mg/liter Calcium ions;
0.06-0.15 mg/liter Lithium ions; and
10-100 mg/liter Potassium ions, in said distilled water.
19
PCT/US1998/003347 1998-02-20 1998-02-20 Mineralized drinking water and method of making same WO1999042002A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/US1998/003347 WO1999042002A1 (en) 1998-02-20 1998-02-20 Mineralized drinking water and method of making same
AU66615/98A AU6661598A (en) 1998-02-20 1998-02-20 Mineralized drinking water and method of making same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/003347 WO1999042002A1 (en) 1998-02-20 1998-02-20 Mineralized drinking water and method of making same

Publications (1)

Publication Number Publication Date
WO1999042002A1 true WO1999042002A1 (en) 1999-08-26

Family

ID=22266430

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/003347 WO1999042002A1 (en) 1998-02-20 1998-02-20 Mineralized drinking water and method of making same

Country Status (2)

Country Link
AU (1) AU6661598A (en)
WO (1) WO1999042002A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003059092A1 (en) * 2002-01-17 2003-07-24 Yury Anatolievich Rakhmanin Artificially mineralised drinking water
NL1023522C2 (en) * 2003-05-23 2004-11-24 Sara Lee De Nv Mineral concentrate.
EP1492420A1 (en) * 2002-04-09 2005-01-05 Belair Biotechnology PTY Ltd Manufactured mineral water composition
US7318893B2 (en) 2001-12-12 2008-01-15 Sara Lee/De N.V. Apparatus for offering and dispensing mineral water suitable for consumption

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4325975A (en) * 1979-12-31 1982-04-20 Lindon John A Mineralized drinking water and method of making same
US4540584A (en) * 1982-12-28 1985-09-10 Nobuo Someya Composition for promotion of health
US4738856A (en) * 1985-05-13 1988-04-19 Nutrition Technologies, Inc. Beverage and method for making a beverage for the nutritional supplementation of calcium in humans
US5294606A (en) * 1992-11-24 1994-03-15 Reliv' International Inc. Isotonic energy composition and method to use same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4325975A (en) * 1979-12-31 1982-04-20 Lindon John A Mineralized drinking water and method of making same
US4540584A (en) * 1982-12-28 1985-09-10 Nobuo Someya Composition for promotion of health
US4738856A (en) * 1985-05-13 1988-04-19 Nutrition Technologies, Inc. Beverage and method for making a beverage for the nutritional supplementation of calcium in humans
US5294606A (en) * 1992-11-24 1994-03-15 Reliv' International Inc. Isotonic energy composition and method to use same

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7318893B2 (en) 2001-12-12 2008-01-15 Sara Lee/De N.V. Apparatus for offering and dispensing mineral water suitable for consumption
WO2003059092A1 (en) * 2002-01-17 2003-07-24 Yury Anatolievich Rakhmanin Artificially mineralised drinking water
EP1492420A1 (en) * 2002-04-09 2005-01-05 Belair Biotechnology PTY Ltd Manufactured mineral water composition
EP1492420A4 (en) * 2002-04-09 2006-02-08 Belair Biotechnology Pty Ltd Manufactured mineral water composition
NL1023522C2 (en) * 2003-05-23 2004-11-24 Sara Lee De Nv Mineral concentrate.
WO2004103097A2 (en) * 2003-05-23 2004-12-02 Sara Lee/De N.V. Mineral concentrate
WO2004103097A3 (en) * 2003-05-23 2005-02-10 Sara Lee De Nv Mineral concentrate

Also Published As

Publication number Publication date
AU6661598A (en) 1999-09-06

Similar Documents

Publication Publication Date Title
US4107346A (en) Dietary salt compositions
Pérez-Granados et al. Silicon, aluminium, arsenic and lithium: essentiality and human health implications
Klevay Hypercholesterolemia in rats produced by an increase in the ratio of zinc to copper ingested
Clement et al. Iron status and sports performance
McDonald et al. Wine versus ethanol in human nutrition. I. Nitrogen and calorie balance
Sutherland et al. Determining human dietary requirements for boron
US20030119913A1 (en) Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof
Peereboom General aspects of trace elements and health
US20070224292A1 (en) Extended effect ergogenic drink
US5786006A (en) Mineralized drinking water and method of making same
Shukla et al. Effect of latent iron deficiency on 5‐hydroxytryptamine metabolism in rat brain
CA2601103A1 (en) Supplementary food composition
Shukla et al. Effect of latent iron deficiency on metal levels of rat brain regions
US20080139657A1 (en) Method for increasing serotonin levels in a person by administration of a composition incorporating (-)hydroxycitric acid, and related compositions thereof
WO1999042002A1 (en) Mineralized drinking water and method of making same
Colin et al. Effect of dietary zinc and protein levels on the utilization of zinc and copper by adult females
McDonald et al. Wine versus ethanol in human nutrition III. Calcium, phosphorus, and magnesium balance
AU2002305132B2 (en) Methods for increasing serotonin levels by administering (-)-hydroxycitric acid
Bogden et al. Effect of chronic ethanol ingestion on the metabolism of copper, iron, manganese, selenium, and zinc in an animal model of alcoholic cardiomyopathy
Ginter Optimum intake of vitamin C for the human organism
Mutuma et al. Chromium in food, nutrition and health‐an introduction
JP3868916B2 (en) Method for separating and extracting hardness component and nutritional supplement food containing hardness component
Widhalm et al. Metabolic effects of a very low calorie diet in obese children and adolescents with special reference to nitrogen balance.
Hämäläinen et al. Alterations in electrolyte and iron metabolism in the rat in relation to peroral administration of galactitol, mannitol and xylitol
Bistrian Recent developments in the treatment of obesity with particular reference to semistarvation ketogenic regimens

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA